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Gastroesophageal reflux disease (GERD) is the most com-
mon cause of noncardiac chest pain (NCCP) and is present 
in up to 60% of patients with NCCP in Western countries. 
In Korea, after a reasonable cardiac evaluation, GERD is 
reported to underlie 41% of NCCP cases. Typical reﬂ  ux symp-
toms are frequent in Korean patients suffering from NCCP. 
Therefore, a careful history of the predominant symptoms, 
including heartburn and acid regurgitation, is relatively in-
dicative of the GERD diagnosis in Korea. In Korea, in contrast 
to Western countries, patients aged 40 years and over who 
have been diagnosed with NCCP but who are without alarm-
ing features should undergo endoscopy to exclude gastric 
cancer or peptic ulcers because of the higher prevalence of 
peptic ulcer disease and gastric cancers in the region. In a 
primary care setting, in the absence of any alarming symp-
toms, a symptomatic response to a trial of a proton pump 
inhibitor (PPI) is sufficient for the presumptive diagnosis of 
GERD. In addition, the optimal duration of a PPI test may 
be at least 2 weeks, as GERD symptoms tend to be less 
frequent or atypical in Korean patients than in patients from 
Western countries. In patients diagnosed with GERD-related 
NCCP, long-term therapy (more than 2 months) with double 
the standard dose of a PPI is required to alleviate symptoms. 
Esophageal dysmotility is relatively uncommon, and pain 
modulators seem to offer significant improvement of chest 
pain control in non-GERD-related NCCP. Most traditionally 
available tricyclics or heterocyclics have many undesirable 
effects. Therefore, newer drugs with fewer side effects (for 
example, the serotonin - norepinephrine reuptake inhibitors) 
may be needed. (Gut Liver 2012;6:1-9)
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INTRODUCTION
Following a reasonable cardiac evaluation, noncardiac chest 
pain (NCCP) is defined as a recurring angina-like or subster-
nal chest pain which is believed to be unrelated to the heart.
1-3 
It affects approximately one-third of the population during 
lifetime.
3,4 It is a benign condition with an estimated 10-year 
mortality of less than 1%.
5 However, the associated morbidity is 
very high, mainly resulting from inability to work and from the 
use of health care services.
6 Several pathophysiological mecha-
nisms have been suggested, including gastroesophageal reflux 
disease (GERD), esophageal motility disorders, visceral hyper-
algesia, psychiatric disturbances, abnormal cerebral processing 
of the visceral stimulation, and disrupted autonomic activity.
7,8 
The diagnosis and management of patients with NCCP is a 
frequent and perplexing problem for clinicians. Even after a 
reasonable cardiac evaluation, many patients continue to pres-
ent a diagnostic and therapeutic challenge to their primary care 
physicians. These patients are frequently highly debilitated and 
tend to use a disproportionate level of health care resources, 
including recurrent doctor and emergency room visits, hospital-
izations, and prescription medication, leading to indications of 
poor satisfaction with their medical care.
9,10
GERD is known to be the most common cause of NCCP.
1,11,12 
It is known to be present in up to 60% of patients with NCCP 
in the world.
13 Similarly, in a prospective analysis conducted 
in Korea in 58 patients with NCCP, 41% were diagnosed with 
GERD based on upper endoscopy and 24-hour esophageal pH 
monitoring (Fig. 1).
14 Concerning age factors, the population-
based study by Eslick et al.
3 showed that the prevalence of 
NCCP tended to decrease with increasing age. Moreover, young 2  Gut and Liver, Vol. 6, No. 1, January 2012
age may be one of the potential risk factors for NCCP.
15 Inter-
estingly, in a recent report in Korea, the incidence of GERD was 
reported to be lower in young patients suffering from NCCP, 
compared with middle aged patients.
16 
DIAGNOSIS
The causes of NCCP are diverse. The esophagus has been 
determinned to be the major source of NCCP, with GERD as 
the most common cause. After cardiac evaluation, the avail-
able diagnostic tests include upper endoscopy, conventional 
esophageal manometry, ambulatory 24-hour esophageal pH 
monitoring, and combinations of the above. A short-term clini-
cal trial using a high-dose proton pump inhibitor (PPI) has been 
also used as a useful tool for diagnosing GERD-related NCCP.
17 
However, these diagnostic tests have some limitations, and none 
of these tests can measure all aspects of NCCP. Recently, the 
advent of combined esophageal impedance-pH metering and 
high-resolution manometry (HRM) has been introduced. 
1. Typical reﬂ  ux symptoms in Korea 
NCCP entails a complex set of symptoms, which, in its broad-
est context, includes patients with heartburn, acid regurgita-
tion, dysphagia, dyspepsia, pleurisy, and others. Among these, 
typical reflux symptoms (heartburn or acid regurgitation) are 
significantly and independently associated with the presence of 
NCCP. Heartburn and acid regurgitation, the principal symp-
toms of GERD, has been traditionally considered less common 
in Asia.
1,12,18 In North American studies,
13 most patients with 
GERD-related NCCP have typical reflux symptoms. In contrast, 
Chinese patients with GERD-related NCCP rarely present with 
typical reflux symptoms.
12 This may be related to the fact that 
there is no direct translation of the word ‘heartburn’ in most 
Asian languages. However, in our recent study, a through 
symptom assessment elicited the presence of “heartburn” and 
“acid regurgitation” in patients initially suspected to have “an-
gina.”
14 Thus, 41% of the patients with NCCP presented with 
typical reflux symptoms. In this study, typical reflux symptoms 
made GERD-related NCCP more likely presenting high values 
of sensitivity and specificity. The ability of typical reflux symp-
toms to heighten the pretest probability of GERD-related NCCP 
is impressive in Korean population,
14 although the sensitivity of 
these symptoms (67%) is lower than that of the PPI test (80%) 
that was reported by a recently published meta-analysis of con-
trolled studies.
19
Chest pain characteristics alone may not be useful in differen-
tiating NCCP from cardiac chest pain,
20 therefore, these charac-
teristics may not make the diagnosis of GERD-related NCCP,
1,12 
by themselves and their clinical value is limited, in the absence 
of other tests. Nevertheless, in patients suffering from NCCP, 
with or without typical reflux problems, a careful symptom as-
sessment based on chest pain characteristics may be useful for 
general practitioners because it is easy to apply and may pro-
vide support for other diagnostic tests, assisting with the clinical 
judgement. However, some Korean patients may complain of 
epigastric soreness or chest discomfort when referring to heart-
burn. During patient interviews, first of all, interviewers should 
be cautious in the way in which they use and interpret the term 
“heartburn,” because many patients do not understand the 
meaning of the term. A careful history of predominant symp-
toms including heartburn and acid regurgitation is relatively 
indicative of the diagnosis of GERD in Korea. When symptoms 
are less clear-cut, an empirical trial of PPIs would be extremely 
helpful.
14
2. Upper endoscopic evaluation with or without alarm 
symptoms 
Upper endoscopy is commonly used in clinical practice as 
the first diagnostic tool to evaluate subjects referred for NCCP. 
However, many authorities believe that the yield of upper en-
doscopy in NCCP patients is very low. This general perception 
is based on very few studies that are commonly limited to one 
center’s experience and include a very small number of partici-
pants.
12,17,21-24 Studies that assessed endoscopic findings in NCCP 
patients reported a wide range of esophageal mucosal findings. 
Wong et al.
12 reported a low incidence of erosive esophagitis 
(2.56%) among Chinese patients with NCCP who underwent up-
per endoscopy. However, other studies that assessed the perfor-
mance of a PPI therapeutic trial in NCCP reported that esopha-
Fig. 1. Upper gastrointestinal evaluation. Gastroesophageal reflux 
disease (GERD)-related noncardiac chest pain (NCCP) is found in 24 
(41%) of 58 subjects on upper endoscopy and/or ambulatory 24-hour 
esophageal pH monitoring. Esophageal motility disorder is found in 
24 subjects (41%), including 18 with ineffective esophageal motility, 
4 with nutcracker esophagus, one with hypertensive lower esophageal 
sphincter (LES), and one with achalasia. GERD-associated esophageal 
dysmotility is found in 11 (19%) patients, and non-GERD-associated 
esophageal dysmotility is found in only 13 subjects (22%).
Non-GERD, non-GERD-related NCCP; Hyper LES, hypertensive LES; 
Nutcracker, nutcracker esophagus; IEM, ineffective esophageal motil-
ity.Kim JH, et al: Noncardiac Chest Pain in Korea  3
geal erosions were documented in 15-34% of the patients.
17,25,26 
Recently, a total number of 3,688 consecutive patients under-
going upper endoscopy for NCCP were analyzed. Of the NCCP 
patients, 44.1% had normal upper endoscopy, 28.6% showed a 
hiatal hernia, 19.4% erosive esophagitis, 4.4% Barrett’s esopha-
gus, and 3.6% stricture/stenosis. Most of the endoscopic find-
ings in NCCP were GERD-related.
27 
Presently, upper endoscopy of the NCCP patients without 
reported alarm symptoms (dysphagia, odynophagia, anorexia, 
and weight loss) is not recommended as a necessary diagnostic 
step in the workup of NCCP. Prompt endoscopy in patients with 
alarm symptoms results in a significant yield of cancer and of 
serious benign diseases such as peptic ulcer, stricture, and severe 
esophagitis (13%).
28 In the Asia-Pacific region, including Korea, 
patients with alarm features are likely to have gastric diseases 
rather than esophageal diseases due to the higher prevalence of 
peptic ulcer disease and gastric cancer in the region. Neverthe-
less, alarm features have a low predictive value and suggest ad-
vanced, rather than early, malignancy.
29 Therefore, every patient 
with NCCP had better undergo endoscopy. Diagnostic strate-
gies in Korea must take into account the coexistence of GERD-
related NCCP with other common conditions, such as gastric 
cancer and peptic ulcer. There is a need to perform endoscopy if 
upper gut symptoms, including NCCP, are persistent or relapse 
frequently.
Upper endoscopy only identifies a low level of upper gas-
trointestinal pathology, and the usefulness of upper endoscopy 
for the evaluation of NCCP has been questioned.
12,30 However, 
patients with NCCP are still commonly referred for upper en-
doscopy; we believe it’s a useful screening test, as it enables the 
direct visualization of mucosal injury and facilitates guidance 
for treatment.
3. The PPI test and its optimal duration
An empirical trial with a PPI (the PPI test) was introduced as 
a non-invasive, readily available alternative diagnostic tool for 
NCCP.
17 The test, which utilizes a short course of a high-dose 
PPI, was found to be highly sensitive and specific for diagnos-
ing GERD-related NCCP (Table 1).
19,31 Several observations have 
confirmed the usefulness of the PPI test for the diagnosis of 
NCCP.
11,17,19 It is readily available for primary care physicians 
and increases their role in evaluating and treating patients suf-
fering from GERD-spectrum disorders. It offers significant cost 
savings when compared to other diagnostic tests. As well, in 
Asia, it has been demonstrated that PPI test is a simple and 
clinically practical method for diagnosing GERD.
32 However, the 
studies reporting on the empirical trials of PPI defined differ-
ently the “successful” reduction of GERD symptoms. In addition, 
there is little information on whether different doses of PPIs 
and the length of treatment with the PPIs made a difference in 
diagnosing GERD.
33 Because of the differences in results from 
previous studies, some believe that the symptomatic response to 
the PPI test does not confidently diagnose GERD. The optimal 
duration of the PPI test has not been determined fully. In several 
studies, the duration has been about 7 days.
34 Earlier pharma-
cological studies with therapeutic doses of PPI showed that this 
duration is long enough to reach a steady-state inhibition of 
acid secretion.
25 Therefore, 7 days are probably long enough to 
see the effects of the PPI and reach a diagnosis in patients with 
symptoms that occur frequently.
21,35 However, it may be too 
Table 1. PPI Test Performance Summaries in Noncardiac Chest Pain
19
Study No.
PPI, dose,
duration
Study
design
GERD, 
%
Responder
Reference
standard(s)
Sensitivity, 
%
Specificity, 
%
PPV,
%
NPV,
%
LR+ LR-
Fass (1998) 39 Omeprazole,
60 mg, 1 wk
RCT,
crossover
62 ＞50% pH-metry,
 endoscopy
78 86 90 71 5.48 0.25
Bautista (2004) 40 Lansoprazole,
90 mg, 1 wk
RCT,
crossover
45 ＞50% pH-metry,
 endoscopy
78 91 88 83 8.56 0.24
Fass (2002) 20 Rabeprazole,
40 mg, 1 wk
RCT,
crossover
60 ＞50% pH-metry,
 endoscopy
83 75 83 75 3.33 0.22
Pandak (2002) 44 Omeprazole,
80 mg, 2 wk
RCT,
crossover
53 ＞50% pH-metry,
 endoscopy
95 61 73 92 2.44 0.08
Squillace (1993) 17 Omeprazole,
80 mg, 1 day
RCT,
crossover
76 ＞50% pH-metry 69 75 90 43 2.77 0.41
Xia (2003) 36 Lansoprazole,
30 mg, 4 wk
RCT, 
parallel group
33 ＞50% pH-metry 92 67 58 94 2.75 0.13
Chambers (1998) 31 Omeprazole,
40 mg, 6 wk
Open label 17 No a priori
definition
pH-metry   0 68   0 76 0 1.46
Dickman (2005) 35 Rabeprazole,
40 mg, 1 wk
RCT,
crossover
35 ＞50% pH-metry,
 endoscopy
75 90 83 75
PPI, proton pump inhibitor; GERD, gastroesophageal reflux disease; PPV, positive predictive value; NPV, negative predictive value; LR+, positive 
likelihood ratio; LR-, negative likelihood ratio; RCT, randomized controlled trial.4  Gut and Liver, Vol. 6, No. 1, January 2012
short of a time interval in patients with less frequent symptoms 
and in patients with atypical symptoms, such as GERD-related 
laryngeal or upper respiratory symptoms.
22,36
In the study by Fass et al., the therapeutic trial of the PPI 
lasted only 7 days in the NCCP subjects who had at least 3 epi-
sodes per week.
21,23,35,37 Consequently, the one week PPI test may 
be most useful for patients with frequent chest pain symptoms. 
However, in all patients who report chest pain irrespective of 
its frequency, the one week PPI trial may not be long enough 
to diagnose GERD-related NCCP. It is not suggesting that the 
NCCP patients should complete a full period of 8 weeks of PPI 
treatment before determining the beneficial effect of the medi-
cation. However, the time frame reported by Fass et al.
17 may be 
too short.
30 Especially in Korea or in Asia in general, compared 
with Western countries, a larger number of patients may have 
infrequent chest pain
2,24,25,38,39 and the above diagnostic guide-
lines would exclude many of these patients. Hence, we agree 
that the duration of the PPI test may highly depend on the 
frequency of the symptom.
6 In our recent uncontrolled trial, the 
two-week rabeprazole trial resulted in symptom improvement 
in 81% of the GERD-related NCCP patients and this result was 
statistically significant compared with the non GERD-related 
NCCP patients.
40 However, for the one-week rabeprazole trial, 
only 50% of the GERD-related NCCP patients responded to the 
PPI treatment (Figs 2 and 3).
40 These data suggest that PPI test 
remains the best available diagnostic tool for patients with, at 
least weekly, NCCP suspected GERD, but that such a trial should 
extend for at least 2 weeks.
4. Are other tests useful?
1) Manometry
The relationship between NCCP symptoms and motility 
abnormalities is known to be even more problematic. These 
were reflected in the American Gastroenterological Association 
guidelines for esophageal manometry, which recommended that 
manometry should not be used as the initial test for the evalu-
ation of the patients with NCCP.
2,41 In our study, the specific 
esophageal motility disorders, such as achalasia, nutcracker 
esophagus, and hypertensive lower esophageal sphincter (LES) 
were found in only 10% of the investigated patients.
14 Even 
though esophageal manometry may be used to ensure the ac-
curate placement of the ambulatory monitoring probes and may 
be helpful prior to antireflux surgery, esophageal manometry is 
not generally used to diagnose GERD in a primary setting.
HRM allows for continuous measurements from a large num-
ber of closely spaced sensors connected to a software capable of 
analyzing large volumes of pressure data; it is easier to perform 
than a regular esophageal manometric investigation because 
a pull-through is not necessary. However, there is no current 
Fig. 2. A comparison of the proton pump inhibitor (PPI) test between gastroesophageal reflux disease (GERD)-related noncardiac chest pain (NCCP) 
and non-GERD-related NCCP groups. During the second week of the PPI trial (B), the fraction of positive PPI tests is significantly higher in the 
GERD-related NCCP group (81%) than in non-GERD-related NCCP group (27%) (p=0.001). However, during the first week of the PPI trial (A), there 
is no significant difference between the two groups (GERD vs non-GERD=50% vs 23%, p=0.1).
Fig. 3. The receiver operating characteristic (ROC) curve of the proton 
pump inhibitor (PPI) test for gastroesophageal reflux disease (GERD)-
related noncardiac chest pain during the first week (A) and the sec-
ond week (B). The reduction in chest pain corresponded to 0.78 in the 
area under ROC with an accuracy of 77.1% during the second week 
of the PPI test. Additionally, there is a significant difference between 
the areas under the ROC curves for the first and second weeks of the 
PPI test (p<0.05).Kim JH, et al: Noncardiac Chest Pain in Korea  5
available data to show an increased diagnostic yield of HRM 
when compared with standard manometry in the evaluation of 
patients with NCCP. On the other hand, if there is suspicion of 
achalasia, diffuse esophageal spasm, or nutcracker esophagus, 
HRM might supply more prognostic information than standard 
manometry.
42
2) Ambulatory 24-hour esophageal pH monitoring 
Ambulatory 24-hour esophageal pH monitoring is generally 
thought to be the most accurate method for the identification 
of GERD in patients with NCCP.
43,44 Unfortunately, this test is 
limited by a lack of physician and patient acceptance, a lack of 
standardization (i.e., variability in what is considered normal 
and abnormal), and an inability to determine the true sensitivity 
and specificity of the technique.
1,45 A negative ambulatory pH 
study off therapy helps to exclude GERD if a PPI test fails.
3) Combined esophageal impedance-pH metering 
Although conventional pH monitoring can quantify esopha-
geal acid exposure and can be used to evaluate the association 
between symptoms and acid reflux, it cannot reliably detect 
non-acid reflux.
46 Recently, the advent of combined esophageal 
impedance-pH metering has allowed the detection of non-acid 
reflux, as well as acid reflux. The detection of reflux episodes 
by changes in intraluminal resistance to alternating current (i.e., 
impedance), combined multichannel intraluminal impedance 
(MII) and pH monitoring offers the opportunity to detect bolus 
exposure (both acid and non-acid reflux episodes) and to evalu-
ate the relationship between symptoms and reflux.
46 Refluxate 
presence, distribution, and clearing are primarily detected by 
MII-pH, and can be simply characterized as acid or non-acid, 
based on the pH change, and as a liquid, gas, or a mix, based 
on the MII.
47 In our recent data, combined impedance-pH moni-
toring improved both the detection and characterization of the 
NCCP and suggested that pathological bolus exposure plays a 
major role in eliciting NCCP.
48
TREATMENT
The treatment of patients with an esophageal source of chest 
pain remains a challenging problem. The management of func-
tional esophageal chest pain is largely empirical. Because GERD 
is the most common cause of esophageal chest pain, anti-reflux 
therapy plays an important role in the diagnosis and treatment 
of the patients with NCCP. In patients with non GERD-related 
NCCP, treatment should be targeted to esophageal motility dis-
orders or visceral hyperalgesia, because esophageal motility dis-
orders or visceral hyperalgesia are thought to play an important 
role in the genesis of the NCCP.
49,50
1. The treatment of GERD-related NCCP using PPIs
The treatment of GERD-related NCCP should involve life style 
modification and pharmacological intervention. Elevating the 
head of the bed at night, reducing fat intake, stopping smoking, 
and avoiding foods that exacerbate reflux have been shown to 
decrease reflux symptoms.
49
The PPIs are the most efficacious medical intervention for 
GERD. Studies have shown repeatedly and consistently that 
PPIs are superior to histamine 2 receptor antagonists (H2RAs) 
in healing the esophageal mucosa and relieving GERD-related 
symptoms in patients with GERD.
51-53 In a meta-analysis, the 
authors demonstrated that after 12 weeks of treatment, heal-
ing rates were 83.6% with PPIs, 51.9% with H2RAs, 39.2% with 
sucralfate, and 28.2% with placebo.
54 In addition, the treatment 
with PPIs resulted in healing rates of esophageal inflammation 
and relief of heartburn symptoms that were two-fold higher 
than what was observed in patients receiving H2RAs. Similarly, 
PPIs demonstrated superiority in relieving heartburn symptoms 
in patients with non erosive reflux disease (NERD), when com-
pared to H2RAs.
55-57 Even when ‘soft’ clinical endpoints were 
used, such as average heartburn severity score or days without 
heartburn, the PPIs were significantly better than the H2RAs. 
The superiority of the PPIs over the H2RAs in the treatment of 
the erosive reflux disease was not limited to acute therapy, but 
has also been demonstrated in maintenance studies over a pe-
riod of time as long as 11 years.
58 Similar comparative trials in 
NERD are not currently available. 
Laparoscopic fundoplication relieves heartburn and acid re-
gurgitation in most patients with GERD, but its effect on the 
chest pain is less clear. The published data report only short-
term outcomes from a limited number of patients, usually suf-
fering from a mild form of the disease. These therapies are con-
sidered experimental and should not be routinely performed.
1
Therefore, in patients with GERD-related NCCP, long term 
therapy (more than 2 months) with commonly double the 
standard dose of a PPI is preferentially required to relieve their 
symptoms.
2. The treatment of non GERD-related NCCP using a pain 
modulator
Anticholinergic drugs, such as atropine, L-hyoscyamine, and 
pirenzepine, induce a decrease in the amplitude of the esopha-
geal peristalsis and in the LES pressure, as seen with manom-
etry; although they may be useful for the treatment of hyper-
contractile esophageal disorders, there is not enough published 
data examining their value in the symptomatic management of 
the patients with NCCP. There are very few clinical trials inves-
tigating the use of smooth muscle relaxants in the treatment of 
the NCCP; when data exists, it mostly demonstrates a transient 
effect. Injection of the botulinum toxin, a potent local anti-
cholinergic agent, was introduced for the treatment of patients 
suffering from NCCP without achalasia or reflux-related spastic 
esophageal disorders. Some studies showed favorable outcomes, 
however, placebo-controlled trials are needed to confirm re-6  Gut and Liver, Vol. 6, No. 1, January 2012
sults.
49
Psychological or psychiatric disorders may be either the cause 
or the effect of the NCCP in many patients. Nevertheless, reli-
able diagnosis procedures may not be easily applied in acute 
situations. Despite the presence of extensive evidence linking 
visceral hypersensitivity and non GERD-related NCCP, the 
mechanism underlying visceral hypersensitivity has not been 
fully elucidated. This problem makes the treatment of the non 
GERD-related NCCP quite difficult. Indeed, therapeutic gains 
with the PPI treatment were obtained in only 9-39% of the pa-
tients with non GERD-related NCCP.
11,25,27 Hence, the principal 
treatment of the non GERD-related NCCP moved towards pain-
modulating agents, such as psychotropic drugs or adenosine 
receptor antagonists, on the basis that the underlying mecha-
nism was increased pain perception or visceral hyperalgesia.
59,60 
Antidepressants have been used as pain modulators to treat 
patients with esophageal disorders causing chest pain. At low 
doses, antidepressants have beneficial effects in the treatment 
of the chronic pain syndromes of somatic and visceral origin. 
The majority of the traditionally available tricyclics or hetero-
cyclics have many undesirable effects. Therefore, newer drugs 
with mitigated side effects are needed. Patients with NCCP are 
more likely to present with hypochondriasis, anxiety, and panic 
disorders. Hence, psychological treatment in the form of reas-
surance has been the mainstay of the management of the NCCP. 
Recently, in a randomized, double-blind, placebo-controlled, 
crossover trial, we evaluated the clinical efficacy of venlafaxine, 
a serotonin-norepinephrine reuptake inhibitor, for functional 
chest pain in young adult patients. We found that venlafaxine 
hydrochloride resulted in a significant decrease of the symptom 
score, with endurable side effects, compared with the efficacy of 
placebo (Fig. 4).
61
Fig. 4. Mean symptom intensity score per week for sequence A (venlafaxine first and placebo second) (A) and sequence B (placebo first and ven-
lafaxine second) groups (B), respectively. The linear mixed model with a random subject effect is performed to determine the carryover effect, the 
period effect, and the treatment effect of the drug for the ranks of the symptom intensity score in the repeated measure cross-over design. Venla-
faxine treatment resulted in a significantly lower symptom intensity score when compared with the placebo treatment (p<0.001).
Fig. 5. Proposed diagnostic evalu-
ation of patients with noncardiac 
chest pain (NCCP) in Korea.
GI, gastrointestinal; GERD, gastro-
esophageal reflux disease; PPI, pro-
ton pump inhibitor.Kim JH, et al: Noncardiac Chest Pain in Korea  7
SUMMARY
Evaluation for esophageal disorder in patients with NCCP 
should be undertaken after a cardiac cause has been excluded. 
The initial evaluation with endoscopy is warranted irrespective 
of alarm symptoms. Then, GERD should be excluded by using 
the PPI test. If the PPI test is negative or the patient did not 
respond to empirical therapy, esophageal manometry could be 
performed primarily to exclude esophageal motility disorders, 
such as achalasia; pH testing has a limited role in evaluating 
patients who failed intense PPI treatment.
Treatment of the NCCP remains a difficult problem due to 
the heterogeneous nature of the disorder. Gastroesophageal 
reflux is the best studied condition contributing to the NCCP. 
Pharmacological trials of acid inhibition show a robust response 
rate for patients with GERD-related NCCP. In patients with non 
GERD-related NCCP, treatment should be targeted to esophageal 
motility disorders or visceral hyperalgesia. However, there are 
not enough clinical trials to date. The role of the newly reported 
serotonin and adenosine receptor pathway opens another op-
portunity for further research to better understand the neu-
rotransmitters involved in the genesis of the visceral chest pain 
(Fig. 5).
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